FLEX LTD.

# Signal Note: Eventide Initiates FLEX Position **Context:** Flex Ltd. is a contract manufacturer (CDMO) with significant exposure to biotech/pharma production, not a drug developer. Eventide's $13.4M entry suggests conviction in outsourced manufacturing tailwinds, likely driven by continued biotech funding cycles and capacity constraints in GLP-1 production or other high-demand therapeutics. **Catalyst timing:** No imminent binary events; this is a thematic play on sustained biotech spending and manufacturing demand through 2024-2025.